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We report three cases of neovascular glaucoma secondary to central retinal artery occlusion (CRAO) which were 
effectively managed with intravitreal bevacizumab (IVB) followed by panretinal photocoagulation (PRP). Neovascular 
glaucoma without peripheral anterior synechiae developed between one and five weeks following CRAO onset. All 
patients received 0.75 mg (0.03 ml) IVB. In all patients, complete regression of the iris and anterior chamber angle 
neovascularization was confirmed within one week. PRP was applied two weeks after the injection. The follow-up 
period was four to seven months (average, five months). Intraocular pressure was controlled in all patients using 
topical antiglaucoma medications alone. However, one patient experienced a recurrence of neovascularization three 
months after the initial combination treatment. This patient received another IVB injection and additional PRP, and 
the recurrent neovascularization resolved. There were no local or systemic adverse events in any patients. Therefore, 
intravitreal bevacizumab may be an effective adjunct in the treatment of neovascular glaucoma associated with CRAO.
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Ischemic retinopathies can cause new vessel growth on the 
iris and anterior chamber angle that can lead to neovascular glau-
coma (NVG). Central retinal artery occlusion (CRAO) can also 
cause neovascularization of the iris (NVI) and NVG as a result 
of ocular ischemia, with an incidence of 1 to 20%.
1-3 The disease 
management usually attempts to control the ocular ischemia 
using panretinal photocoagulation (PRP).
4 However, PRP often 
takes several weeks to induce neovascular regression. During 
this period, progressive angle closure and optic nerve damage 
may occur as a result of the elevated intra-ocular pressure (IOP).
5
Recently, the pathogenesis of NVG has been linked to a lo-
cally produced angiogenic growth factor: vascular endothelial 
growth factor (VEGF).
6 Intravitreal administration of bevaci-
zumab (Avastin, Genentech, Inc., San Francisco, CA, USA), a 
recombinant anti-VEGF, has been reported to be beneficial in 
the treatment of  NVG. In a review of the literature, we noted that 
bevacizumab causes early-onset neovascular regression in less 
than one week, and that regression of the NVI may persist for 
four to ten weeks because of its short duration lasting for four 
weeks.
7-11 Given the chronic nature of the ischemic drive in NVG 
and the rapid decline of the effects of bevacizumab, a combina-
tion therapy of intravitreal bevacizumab (IVB) with early onset 
neovascular regression and PRP with a long duration of action 
might be useful in managing NVG.
5,12 Therefore, we used a com-
bination of IVB and PRP for the treatment of new-onset NVG 
associated with CRAO. 
Thus far, there has been no report in the Korean literature 
addressing the use of combination IVB/PRP in the treatment 
of NVG. There has only been one case report describing the 
utility of bevacizumab in one PRP-treated eye with a history of 
proliferative diabetic retinopathy.
11 We describe three cases of 
NVG following CRAO treated with combination IVB/PRP.
Case Report
Case 1
A 51-year-old man with known mild, bilateral nonprolifera-
tive diabetic retinopathy was referred for evaluation of CRAO 
that had developed in his left eye 72 hours prior to presentation. 
His past medical history included systemic arterial hypertension 
and diabetes mellitus for the past 15 years. 
On examination, his best-corrected visual acuity was 0.6 in 
the right eye and hand motion in the left eye. Intraocular pressure 
(IOP) was 14 mmHg bilaterally by Goldmann applanation to-
nometry. Anterior segment evaluation showed no NVI in the left 
eye, and both eyes had open angles. Fundus examination showed 
midperipheral retinal hemorrhages in both eyes. In the left eye, 
the retina was pale with attenuated arteries and a cherry red spot 
at the posterior pole. An intravenous fluorescein angiogram Korean J Ophthalmol Vol.23, No.3, 2009
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Table 1. Summary of cases
　 Case 1 Case 2 Case 3
Age (years) 51 59 75
Sex Male Male Female
Diabetes mellitus + + +
Hypertension + - -
Carotid artery evaluation 70% stenosis of ipsilateral ICA,
*
plaques in bilateral ICA 
70% stenosis of ipsilateral ICA,
50% stenosis of contralateral ICA
No stenosis
IOP
† (mmHg) at pre-NVG
‡ stage 14 - 14
At presentation of NVG
 Vision NLP
§ NLP HM
∏
 IOP (mmHg) 45 40 40
 Neovascularization of iris and angle + + +
One week after IVB
＃
 Vision NLP NLP HM
 IOP (mmHg) 25 18 22
 Neovascularization of iris and angle - - -
At last follow-up
 Vision NLP NLP HM
 IOP (mmHg) 25 15 17
 Neovascularization of iris and angle - - -
Second IVB injection + - -
 Number of IOP-lowering medications 
 at final visit 21 1
 Follow-up period (months) 7 4 4
* ICA=internal carotid artery; 
† IOP=intraocular pressure; 
‡ NVG=neovascular glaucoma; 
§ NLP=no light perception; 
∏HM=hand motion; 
＃ IVB=intravitreal bevacizumab.
showed a delayed arm-to-retina time of 25 seconds and incom-
plete retinal venous filling throughout the test (>6 minutes). 
Choroidal perfusion was normal. Noninvasive carotid exami-
nation delineated 70% stenosis in the left proximal internal 
carotid artery and plaques in both internal carotid arteries. 
Five weeks later, on routine follow-up examination, he re-
turned complaining of ocular pain in his left eye for the previous 
three days. The visual acuity in the left eye had decreased to no 
light perception, and the IOP was 45 mmHg. Neovascularization 
of the iris and angle was noted in the left eye. The retinal whi-
tening and cherry red spot were still present. 
Despite maximal tolerable medical therapy to control intrao-
cular pressure, the patient experienced marked discomfort. Treat-
ment options were explained in detail, and after the patient gave 
consent, an intravitreal injection of 0.75 mg (0.03 ml) of beva-
cizumab was performed in a sterile fashion without anterior 
chamber paracentesis. One week later, there was a complete 
regression of the NVI, and the IOP had decreased to 25 mmHg 
with two topical antiglaucoma medications (dorzolamide/timolol 
fixed combination and brimonidine). PRP consisting of a total 
of 1200 burns was administered in three sessions starting two 
weeks after the injection. Over the next three months, recurrent 
NVI developed, and the patient received another IVB injection 
and additional PRP. Over the course of treatment, the patient 
received 2000 burns in all. Two months after the additional com-
bination therapy, there was no recurrence of NVI, and the IOP 
was 21 mmHg with the same medications.
Case 2
A 59-year-old man with a ten-year history of diabetes mellitus 
was referred for evaluation of decreased vision in the previous 
two weeks and ocular pain for three days. He was normally 
followed for mild diabetic retinopathy in both eyes for the 
past two years.
On examination, his best-corrected visual acuity was no light 
perception in the right eye and 0.8 in the left eye. IOPs were 
40 mmHg in the right eye and 18 mmHg in the left eye by Gold-
mann applanation tonometry. Anterior segment evaluation re-
vealed neovascularization of the iris and angle in the right eye. 
Fundus examination showed CRAO characterized by retinal 
whitening with attenuated arteries and a cherry red spot at the 
posterior pole in the right eye. Both eyes had midperipheral 
retinal hemorrhages. Fluorescein angiography showed normal 
choroidal filling. Retinal arterial filling began at 30 seconds 
after injection, and the retinal vein was not completely filled 
even late in the angiogram. A noninvasive carotid examination 
revealed 70% stenosis of the right internal carotid artery and 
50% stenosis of the left internal carotid artery. 
After obtaining informed consent, bevacizumab (0.75 mg/ 
0.03 ml) was injected. One week after the injection, the NVI 
had regressed, and the IOP was 18 mmHg/AT with two topical M Sagong, et al. BEVACIZUMAB FOR NVG ASSOCIATED WITH CRAO
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antiglaucoma medications (dorzolamide/timolol fixed combi-
nation and brimonidine). PRP was started two weeks after the 
injection. The patient received 1800 burns overfour sessions. 
Four months later, there was no recurrent neovascularization, 
and the IOP was 15 mmHg with one topical antiglaucoma me-
dication (dorzolamide/timolol fixed combination).
Case 3   
A 75-year-old woman presented with a ten-day history of de-
creased visual acuity in her right eye. Her past medical history 
included diabetes mellitus for the last five years.
Her visual acuity was hand motion in the right eye and 0.9 in 
the left eye. IOPs were 14 mmHg in the right eye and 12 mmHg 
in the left eye by Goldmann applanation tonometry. There was 
no anterior chamber reaction or NVI in the right eye. The right 
fundus showed a CRAO characterized by retinal opacification 
of the posterior pole with a cherry red spot. No clinical evidence 
of diabetic retinopathy was present in either eye. Fluorescein 
angiography showed sluggish retinal arterial flow and delayed 
retinal venous filling. Noninvasive carotid examination showed 
no evidence of obstruction. 
Two weeks later, the patient returned for a follow-up exami-
nation. Her visual acuity in the right eye remained hand motion. 
However, the right eye now exhibited NVI and had an IOP of 
40 mmHg. The retinal opacification was still present. After ob-
taining informed consent, bevacizumab (0.75 mg/ 0.03 ml) was 
injected. One week after the injection, the NVI had regressed, 
and the IOP had decreased to 22 mmHg with two topical an-
tiglaucoma medications (dorzolamide/timolol fixed combination 
and brimonidine). PRP was performed in the right eye two 
weeks after the injection. The patient received 1600 burns over 
four sessions. Four months after combination therapy, the visual 
acuity remained hand motion with no recurrent neovasculari-
zation. The IOP was 17 mmHg with one topical antiglaucoma 
medication (dorzolamide/timolol fixed combination). 
Discussion
NVI and the subsequent development of NVG are serious 
complications seen in patients with ischemic retinal disorders 
such as proliferative diabetic retinopathy, central retinal vein 
occlusion and central retinal artery occlusion.
4 The incidence 
of NVI or NVG secondary to CRAO has been reported to be 
in the range of 1 to 20%.
1-3 We reviewed 36 CRAO patients 
seen over a four-year period from January 2004 to August 2008. 
Based on our data, the incidence of NVI or NVG after CRAO 
was 19.4% (7 of 36). This figure may actually be less than the 
true incidence because all 36 patients were not followed-up 
completely; some of them might have developed NVI or NVG 
after discontinuing follow-up. There were seven patients who 
had NVI or NVG after CRAO, and this report describes three 
patients with NVG treated with combination IVB/PRP therapy.
The evidence implicating CRAO as the cause of NVG is 
strong. No ocular neovascularization was present in any of the 
three cases at the time of CRAO. NVI appeared de novo as early 
as two to five weeks after the initial presentation of CRAO. At 
the time of the initial CRAO, Cases 1 and 2 had only mild, non-
proliferative diabetic retinopathy, and Case 3 had no diabetic 
retinopathy upon clinical examination or fluorescein angio-
graphy. Ocular ischemic syndrome was ruled out completely 
in Case 3, who showed no evidence of carotid artery stenosis. 
Cases1 and 2 both had some degree of carotid artery stenosis, 
but the obstruction did not approach the 90% or greater blockage 
that is necessary to induce ocular ischemic syndrome.
13 More 
importantly, there was no delayed choroidal filling on fluore-
scein angiography in any of the three cases.    
NVI and NVG are highly correlated with retinal ischemia, 
which stimulates the production of vascular endothelial growth 
factor (VEGF), a key molecule in ocular neovascularization.
6,14 
Tripathi et al.
6 reported that the level of VEGF in the aqueous 
humor is significantly increased in patients with NVI and NVG, 
and that inhibition of endogenous VEGF is effective in supp-
ressing retinal ischemia-induced NVI. Currently, PRP is the 
gold standard for initial treatment.
4,15,16 VEGF levels are in-
directly reduced after PRP in patients with ischemic retinal di-
sorders.
6 However, PRP alone is not completely successful in 
halting NVI in every patient, especially those with severe and 
rapid neovascular progression.
4 Duker and Brown
15 reported 
regression in 65% of patients after PRP for treatment of NVI 
secondary to CRAO. Therefore, direct targeting of VEGF with 
anti-VEGF pharmacotherapy may be another possible thera-
peutic strategy in the treatment of ocular neovascularization.
17 
Bevacizumab is a full-length humanized monoclonal anti-
body that binds with all isoforms of VEGF.
18 Some studies have 
reported on the short-term efficacy and safety of off-label IVB 
in the treatment for NVI and NVG.
9-11 A marked regression of 
NVI has been shown to occur within one to two weeks after 
the injection. IOP was controlled for the short follow-up period 
in most patients, even those with early-stage NVG. However, 
the effect of bevacizumab on the regression of NVI may be 
transient due to the drug’s short duration of action.
7,8 
Several recent studies have addressed combination IVB/PRP 
therapy for the treatment of NVG.
5,12,19 A combination of IVB 
and PRP can theoretically offer the advantage of early onset 
neovascular regression from the bevacizumab and a long dura-
tion of action from the PRP.
5 In a study comparing same-day 
combination IVB (1.25 mg/0.05 ml)/PRP with PRP alone for 
the treatment of new onset NVG, Ehlers et al.
5 reported that the 
combination treatment group showed a significantly higher fre-
quency and rate of neovascular regression and a significantly 
reduced IOP compared to the PRP-alone group. Gheith et al.
12 
reported six cases of NVG treated with IVB (1.25 mg/0.05 ml) 
that were then followed by PRP approximately one week later. 
In all cases, NVI completely regressed after initial combination 
therapy. However, two cases had a recurrence of NVI after three 
months and five months, respectively. These patients initially 
had inadequate PRP, and the neovascularization recurred when 
the effect of the bevacizumab wore off. 
Based on these observations, we chose to administer com-Korean J Ophthalmol Vol.23, No.3, 2009
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bination IVB/PRP therapy. Although the optimum IVB dose 
remains to be established, previous studies have described 
using up to 2.5 mg without serious adverse systemic or ocular 
events.
20,21 Recent reports have suggested that even smaller 
doses may be sufficient to inhibit intravitreal VEGF and neo-
vascular proliferation.
7,22 Therefore, we performed an injection 
of 0.75 mg of bevacizumab, representing 0.03 ml of a 25 mg/ 
ml concentration, in all patients as an initial treatment for NVG. 
All injections were done without anterior chamber paracentesis 
to avoid its related complications after maximal tolerable medical 
therapy, including mannitolization for elevated IOP. Considering 
the short duration of action associated with small amounts of 
bevacizumab, PRP was routinely started approximately two 
weeks after IVB injection to achieve long-lasting neovascular 
regression. In all of our cases, NVI had completely resolved 
within one week after the initial injection of IVB. NVI regression 
persisted four months later in two of our cases (Cases 2 and 3) 
who received a single injection of IVB followed by PRP. How-
ever, Case 1 showed an NVI recurrence after three months. This 
patient received another IVB injection with additional PRP, 
which resulted in the resolution of the recurrent NVI. It is po-
ssible that, in this patient, subsequent PRP was scheduled but 
was not completed. Because NVI as the main indicator for 
adequate PRP disappears after the initial IVB, the amount of 
subsequent PRP required may have been underestimated.
Recently, Wakabayashi et al.
23 reported a large case study 
in which the patients were followed-up for six to 22 months. 
In the NVI-only group, recurrent NVI was resolved by repeat 
IVB and additional PRP without the development of NVG. 
In the open-angle NVG group, 41% of the patients eventually 
required surgical intervention to stabilize their elevated IOPs, 
despite repeat IVB and PRP and in the closed-angle NVG group, 
93% of the patients underwent surgery. These findings indicate 
that IVB may be effective as the first treatment of choice for 
eyes with NVI and early-stage NVG, but it may be insufficient 
for treating eyes in a pathologically-advanced stage of NVG. 
Our three cases had open-angle NVG associated with CRAO. 
In all of these cases, IOP was controlled with topical antiglau-
coma medications alone without surgical intervention.
In conclusion, we recommend that all CRAO patients be 
followed closely for several months after obstruction, with spe-
cific attention directed toward the development of NVI and 
NVG. If  NVI or NVG is present, combination IVB/PRP therapy 
should be considered. Our report suggests that IVB may be valu-
able in the treatment of NVG because it speeds up the resolution 
of NVI. Furthermore, IVB appears to provide long-term control 
when used in combination with PRP. This report emphasizes 
the need for further prospective, long-term, randomized studies 
examining PRP-only, IVB-only, and IVB/PRP combination 
therapy for the treatment of NVG. 
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